Last reviewed · How we verify
Skin ulcer — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Silvadene | Silver Sulfadiazine | Pfizer | sulfonamide antimicrobial | bacterial cell membrane and cell wall | 1973-01-01 | |
| Sulfadiazine | SULFADIAZINE | Eli Lilly | Sulfonamide Antibacterial [EPC] | 5-hydroxytryptamine receptor 2A | 1941-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Skin ulcer
- Eli Lilly · 1 drug in Skin ulcer
- Pfizer · 1 drug in Skin ulcer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Skin ulcer:
- Skin ulcer treatment updates — RSS
- Skin ulcer treatment updates — Atom
- Skin ulcer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Skin ulcer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/skin-ulcer. Accessed 2026-06-10.
Related
- Skin ulcer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing